Latanoprost Eg (Latanoprost)

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the eye’s ciliary body. This binding enhances the uveoscleral outflow of aqueous humor, which reduces intraocular pressure, the primary therapeutic goal in glaucoma management.

The dosing regimen for Latanoprost Eg is determined by the prescribing clinician. Typically, a single drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

The safety of Latanoprost in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intraocular pressure reduction. Compared with beta‑blocker eye drops, it often provides greater pressure lowering with a different side‑effect profile, making it a first‑line option for many patients.

Latanoprost Eg should be stored at ambient temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Latanoprost is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should avoid touching the tip of the bottle to the eye or any other surface to maintain sterility.

Serious risks, though rare, include ocular inflammation such as uveitis, corneal or macular edema, and severe allergic reactions. Patients should seek immediate medical attention if they experience sudden eye pain, vision changes, or signs of an allergic response.

Latanoprost is contraindicated in patients with known hypersensitivity to the drug or any of its components, and it should be used with caution in individuals with active ocular infections, recent ocular surgery, or a history of uveitis.